Exploring the Urtica dioica Leaves Hemostatic and Wound-Healing Potential. 2017

Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
Laboratory of Biopesticides, Center of Biotechnology of Sfax, University of Sfax, P.O. Box 1177, 3018 Sfax, Tunisia.

The present paper investigated the efficiency of Urtica dioica (U. dioica) on hemostatic and wound healing activities. U. dioica leaf extracts were evaluated for their antibacterial and antioxidant effects as well as their flavonoid and polyphenol content. The hydroethanolic extract (EtOH-H2OE), showing the most potent antibacterial and antioxidant activities in vitro, thanks to its flavonoid and polyphenol richness, was selected for hemostatic and wound healing evaluation. Twenty-four rats completing full-thickness wounds were split into four groups. The wounds were topically treated with saline solution, glycerol, "CICAFLORA," and U. dioica EtOH-H2OE (50 µL/mm2) until day 11. The wound healing effect was assessed by macroscopic, histological, and biochemical parameters. Rats treated with EtOH-H2OE showed fast wound closure (92.39%) compared to the control animals (60.91%) on the 11th day of wounding (P < 0.01). Histopathological and biochemical explorations showed full epidermal regeneration and an improvement of the hydroxyproline content in the U. dioica EtOH-H2OE treated rats. Analysis of fatty acids and sterols by GC-MS showed the presence of unsaturated fatty acids and a high concentration of lupeol known for their involvement in reepithelialization. These results prove the efficiency of U. dioica EtOH-H2OE in wound healing and supported its traditional use.

UI MeSH Term Description Entries
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006490 Hemostatics Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. Antihemorrhagic,Hemostatic,Antihemorrhagics
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.

Related Publications

Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
May 2017, Pakistan journal of pharmaceutical sciences,
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
October 2021, Molecules (Basel, Switzerland),
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
July 2006, Phytotherapy research : PTR,
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
September 2007, Alternative medicine review : a journal of clinical therapeutic,
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
June 2010, Phytotherapy research : PTR,
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
September 2022, Molecules (Basel, Switzerland),
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
June 2022, Journal of diabetes and metabolic disorders,
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
January 2023, Plants (Basel, Switzerland),
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
October 1987, Planta medica,
Karama Zouari Bouassida, and Sana Bardaa, and Meriem Khimiri, and Tarek Rebaii, and Slim Tounsi, and Lobna Jlaiel, and Mohamed Trigui
August 2018, Metabolic brain disease,
Copied contents to your clipboard!